ARECOR AND JDRF SIGN A JOINT RESEARCH, DEVELOPMENT AND COMMERCIALISATION AGREEMENT TO DEVELOP A CO-FORMULATION INSULIN FOR THE TREATMENT OF DIABETES

Link to Full Article Cambridge, UK., 22 October 2019: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research. Under this collaboration, Arecor and JDRF will […]

DOSING COMPLETE IN PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN PRODUCT CANDIDATE AT247 FOR DIABETES

Link to Full Article HEADLINE DATA READOUT EXPECTED Q4 2019 Cambridge, UK.,4 October 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247. Arecor’s AT247 […]

ARECOR SIGNS A NEW FORMULATION EVALUATION AGREEMENT WITH AN EXISTING PARTNER, A MAJOR GLOBAL PHARMACEUTICAL COMPANY

Link to Full Article Cambridge, UK., 9th July 2019: Arecor Ltd (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company. Under this […]

PROACTIVEINVESTORS interview with CEO, Dr Sarah Howell re the dosing of Arecor’s first patient in its Phase I clinical trial of its rapid-acting insulin product candidate, AT247, for the improved treatment of diabetes.

Link to Full Article Arecor, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, announces the initiation of its AT247 Phase I clinical trial and an important next step in the Company’s strategy to develop even faster acting insulins targeted at […]

ULTRA-RAPID ACTING INSULIN PRODUCT CANDIDATE AT247 FOR DIABETES

Link to Full Article Cambridge, UK., 7th May 2019: Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting […]

ARECOR SIGNS A NEW MULTI-PRODUCT COLLABORATION WITH A MAJOR GLOBAL PHARMACEUTICAL COMPANY

Link to Full Article Cambridge, UK., 3rd May 2019: Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology, ArestatTM to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a collaboration with a new major global pharmaceutical partner. Under […]

ARECOR LISTED IN BUSINESS WEEKLY’S ‘KILLER50’

Hot on the heels of our first clinical trials approval, Arecor is delighted to be listed in Business Weekly’s ‘Killer50’, as a leading lifescience innovator. Please see the listing and feature here on Page 12: Link

ARECOR RECEIVES REGULATORY APPROVAL TO INITIATE PHASE I CLINICAL TRIAL FOR ULTRA-RAPID ACTING INSULIN PRODUCT

Cambridge, UK., 20 March 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im […]

ARECOR APPOINTS CHIEF FINANCIAL OFFICER

Cambridge (UK), 11th March 2019, Arecor Limited (‘Arecor’ or the ’Company’), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect […]

Super-fast-acting Prandial Insulin Product Receives £0.5m Innovate UK Boost

Super-fast product addresses critical unmet need in development of next generation artificial pancreas systems” “Novel formulation significantly accelerates absorption of insulin post injection – accelerating the onset of glucose lowering.” Cambridge, UK., 13 February 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for […]